These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38787940)

  • 1. Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes.
    Viode A; Smolen KK; van Zalm P; Stevenson D; Jha M; Parker K; ; Levy O; Steen JA; Steen H
    Sci Adv; 2024 May; 10(21):eadl5762. PubMed ID: 38787940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death.
    Gisby J; Clarke CL; Medjeral-Thomas N; Malik TH; Papadaki A; Mortimer PM; Buang NB; Lewis S; Pereira M; Toulza F; Fagnano E; Mawhin MA; Dutton EE; Tapeng L; Richard AC; Kirk PD; Behmoaras J; Sandhu E; McAdoo SP; Prendecki MF; Pickering MC; Botto M; Willicombe M; Thomas DC; Peters JE
    Elife; 2021 Mar; 10():. PubMed ID: 33704068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19.
    Haljasmägi L; Salumets A; Rumm AP; Jürgenson M; Krassohhina E; Remm A; Sein H; Kareinen L; Vapalahti O; Sironen T; Peterson H; Milani L; Tamm A; Hayday A; Kisand K; Peterson P
    Sci Rep; 2020 Nov; 10(1):20533. PubMed ID: 33239683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes.
    Li Y; Schneider AM; Mehta A; Sade-Feldman M; Kays KR; Gentili M; Charland NC; Gonye AL; Gushterova I; Khanna HK; LaSalle TJ; Lavin-Parsons KM; Lilley BM; Lodenstein CL; Manakongtreecheep K; Margolin JD; McKaig BN; Parry BA; Rojas-Lopez M; Russo BC; Sharma N; Tantivit J; Thomas MF; Regan J; Flynn JP; Villani AC; Hacohen N; Goldberg MB; Filbin MR; Li JZ
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19.
    Palmos AB; Millischer V; Menon DK; Nicholson TR; Taams LS; Michael B; Sunderland G; Griffiths MJ; ; Hübel C; Breen G
    PLoS Genet; 2022 Mar; 18(3):e1010042. PubMed ID: 35239653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics validate circulating GDF-15 as an independent biomarker for COVID-19 severity.
    Bu S; Royston L; Mabanga T; Berini CA; Tremblay C; Lebouché B; Cox J; Costiniuk CT; Durand M; Isnard S; Routy JP
    Front Immunol; 2024; 15():1377126. PubMed ID: 38686386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.
    Bauer W; Weber M; Diehl-Wiesenecker E; Galtung N; Prpic M; Somasundaram R; Tauber R; Schwenk JM; Micke P; Kappert K
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG Antibodies, SARS-CoV-2 Load, and Prognostic Indicators in Patients with Severe and Mild COVID-19 in Japan.
    Kashiwagi K; Maeda T; Yoshizawa S; Sato T; Aoki K; Ishii Y; Tateda K
    J Nippon Med Sch; 2021 Sep; 88(4):380-383. PubMed ID: 33250476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients.
    Park J; Kim H; Kim SY; Kim Y; Lee JS; Dan K; Seong MW; Han D
    Sci Rep; 2020 Dec; 10(1):22418. PubMed ID: 33376242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology.
    Villar M; Urra JM; Rodríguez-Del-Río FJ; Artigas-Jerónimo S; Jiménez-Collados N; Ferreras-Colino E; Contreras M; de Mera IGF; Estrada-Peña A; Gortázar C; de la Fuente J
    Front Immunol; 2021; 12():730710. PubMed ID: 34566994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteome analysis develops novel plasma proteins classifier in predicting the mortality of COVID-19.
    Zeng Y; Li Y; Zhang W; Lu H; Lin S; Zhang W; Xia L; Hu H; Song Y; Xu F
    Cell Prolif; 2024 Jul; 57(7):e13617. PubMed ID: 38403992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study.
    ;
    Sci Immunol; 2021 Aug; 6(62):. PubMed ID: 34376480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.
    Sarif J; Raychaudhuri D; D'Rozario R; Bandopadhyay P; Singh P; Mehta P; Hoque MA; Sinha BP; Kushwaha M; Sahni S; Devi P; Chattopadhyay P; Paul SR; Ray Y; Chaudhuri K; Banerjee S; Majumdar D; Saha B; Sarkar BS; Bhattacharya P; Chatterjee S; Paul S; Ghosh P; Pandey R; Sengupta S; Ganguly D
    Front Immunol; 2021; 12():738093. PubMed ID: 34777349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics of serum-derived extracellular vesicles are associated with the severity and different clinical profiles of patients with COVID-19: An exploratory secondary analysis.
    Paes Leme AF; Yokoo S; Normando AGC; Ormonde JVS; Domingues RR; Cruz FF; Silva PL; Souza BSF; Dos Santos CC; Castro-Faria-Neto H; Martins CM; Lopes-Pacheco M; Rocco PRM
    Cytotherapy; 2024 May; 26(5):444-455. PubMed ID: 38363248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients.
    Contoli M; Papi A; Tomassetti L; Rizzo P; Vieceli Dalla Sega F; Fortini F; Torsani F; Morandi L; Ronzoni L; Zucchetti O; Pavasini R; Fogagnolo A; Volta CA; Bartlett NW; Johnston SL; Spadaro S; Campo G
    Front Immunol; 2021; 12():648004. PubMed ID: 33767713
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolomics study of COVID-19 patients in four different clinical stages.
    Valdés A; Moreno LO; Rello SR; Orduña A; Bernardo D; Cifuentes A
    Sci Rep; 2022 Jan; 12(1):1650. PubMed ID: 35102215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
    ;
    Cell; 2022 Mar; 185(5):916-938.e58. PubMed ID: 35216673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine (Hcy) assessment to predict outcomes of hospitalized Covid-19 patients: a multicenter study on 313 Covid-19 patients.
    Ponti G; Roli L; Oliva G; Manfredini M; Trenti T; Kaleci S; Iannella R; Balzano B; Coppola A; Fiorentino G; Ozben T; Paoli VD; Debbia D; De Santis E; Pecoraro V; Melegari A; Sansone MR; Lugara M; Tomasi A
    Clin Chem Lab Med; 2021 Aug; 59(9):e354-e357. PubMed ID: 33768762
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma Proteins Associated with COVID-19 Severity in Puerto Rico.
    Rosario-Rodríguez LJ; Cantres-Rosario YM; Carrasquillo-Carrión K; Rosa-Díaz A; Rodríguez-De Jesús AE; Rivera-Nieves V; Tosado-Rodríguez EL; Méndez LB; Roche-Lima A; Bertrán J; Meléndez LM
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.